Tag: Refractory Ovarian Cancer

Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancers

— About half of patients responded, duration of response as long as 19 months in three trials

April 5, 2024 9:00 am

By Charles Bankhead

The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers.

The action represents the first tumor-agnostic approval for an antibody-drug conjugate targeting HER2-positive tumors. According … Read more

Personalized cancer vaccine and adoptive T cell therapy benefits patients with advanced ovarian cancer: Study

September 21, 2023 9:00 am

By Andrea S. Blevins Primeau, PhD, MBA

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research … Read more

Ovarian Cancer Chemotherapy Resistance Linked to Stress-Associated Gene Expression Features

February 23, 2022 9:24 am

NEW YORK – A team led by researchers at the University of Helsinki has uncovered stress-related tumor and microenvironment gene expression features that appear to coincide with chemotherapy resistance and shorter progression-free survival in individuals with high-grade serous ovarian cancer.… Read more

Wee1 Inhibitor Gets Win in Tough-to-Treat Ovarian Cancer

January 25, 2021 5:00 pm

By Ian Ingram

Adding the Wee1 inhibitor adavosertib to gemcitabine reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer, a randomized phase II trial showed.

For the primary endpoint of progression-free survival … Read more

Phase I Data of XMT-1536 Supports Continued Development in Ovarian Cancer

September 17, 2020 1:00 pm

Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536 show a 34% objective response rate (ORR) and 79% disease control rate, including two complete responses. … Read more

Non-Chemo Combo Active in Ovarian Cancer

June 6, 2018 7:00 pm

The combination of two targeted agents – the PARP inhibitor niraparib (Zejula) plus the checkpoint inhibitor pembrolizumab (Keytruda) — appears to elicit a durable response among women with heavily pretreated, refractory ovarian cancer, researchers reported here.

About 25% of women … Read more